Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

BACKGROUND: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response. PATIENTS AND METHODS: This single instituti...

Descripción completa

Detalles Bibliográficos
Autores principales: Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, M R, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S B, Harris, A L, Bottini, A, Berruti, A, Generali, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668467/
https://www.ncbi.nlm.nih.gov/pubmed/23579222
http://dx.doi.org/10.1038/bjc.2013.151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668467/
https://www.ncbi.nlm.nih.gov/pubmed/23579222
http://dx.doi.org/10.1038/bjc.2013.151

Ejemplares similares